Good points:
- BTT trial over 80% complete and due for completion in January. (was supposed to finish end of year but that is good enough)
Bad points:
- no cap on bonuses or salaries, especially for director.
- cessation of R&D (this should not have been compromised)
- no strategic partnership agreements reached yet
Overall I'm bullish on VCR and can't believe the price is at this level. Especially when compared to Thoratec capitalisation.
What I would really like is for VCR to obtain a strategic partnership agreement and continue full steam ahead with R&D. I would definitely partake in SPP then.
VCR
ventracor limited
funding plan
Add to My Watchlist
What is My Watchlist?